A Randomized, Double-Blind, Placebo/Active Controlled, Single Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Patients with Various Allergic Diseases
Latest Information Update: 26 Nov 2024
At a glance
- Drugs YH 35324 (Primary) ; Omalizumab
- Indications Chronic urticaria; Cold Urticaria
- Focus Adverse reactions
- Sponsors Yuhan
Most Recent Events
- 26 Sep 2024 Status changed from active, no longer recruiting to completed.
- 19 Sep 2024 Planned End Date changed from 26 Aug 2024 to 19 Nov 2024.
- 19 Sep 2024 Planned primary completion date changed from 26 Aug 2024 to 19 Nov 2024.